title: MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1.
abstract: Clear-cell renal cell carcinoma is a highly treatment-resistant tumor type. Heme oxygenase-1 plays an anti-apoptotic role in cancer chemotherapeutic inducing tumor-progression. The miR-200 family was involved in the process of mesenchymal-epithelial transition (MET) during renal development. In the present study, we demonstrated the regulatory relationship between miR-200c and HO-1. We provided evidences to elucidate that miR-200c could sensitize ccRCC cells to sorafenib or imatinib to inhibit cell proliferation, at least partly by targeting HO-1. Moreover, the correlation between miR-200c and HO-1 expression level and drug resistance in ccRCC was also determined. Combined application with chemotherapeutic drugs, miR-200c, a HO-1 inhibitor, may enhance the efficiency of therapy by promoting both apoptosis and autophagy.
authors.forename: C
authors.initials: C
authors.lastname: Gao
authors.forename: F H
authors.initials: FH
authors.lastname: Peng
authors.forename: L K
authors.initials: LK
authors.lastname: Peng
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D019175:DNA Methylation; D051547:Heme Oxygenase-1 / Q000037:antagonists & inhibitors* / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D035683:MicroRNAs / Q000235:genetics / Q000502:physiology*; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D011401:Promoter Regions, Genetic; D011743:Pyrimidines / Q000494:pharmacology*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; C533896:MIRN200 microRNA, human; D035683:MicroRNAs; D010671:Phenylurea Compounds; D010879:Piperazines; D011743:Pyrimidines; D009536:Niacinamide; D000068877:Imatinib Mesylate; D000077157:Sorafenib; D051547:Heme Oxygenase-1